The share price of Andon Health Co.Ltd(002432) in Zeng Pianan’s corner soared all the way, and several regulatory letters from the exchange still couldn’t stop its rising momentum.
On the morning of December 24, Andon Health Co.Ltd(002432) received the attention letter again. Shenzhen Stock Exchange pointedly pointed out that the company’s “word game” on the interactive easy platform called “in principle, we believe that the company’s antigen detection products can detect Omicron mutant strain”, and asked it to explain the basis.
According to the attention letter, the Shenzhen stock exchange requires the company to explain the basis for the company’s claim that the reagent box products rank first on Amazon’s US website in combination with the methods and standards for the sales ranking of reagent box products on Amazon’s US website, and whether it is inconsistent with the company’s claim that the sales information of the company’s reagent box products is not disclosed on Amazon’s US official platform.
For the phenomenon that the content and meaning of the company’s reply to product quality questions on the interactive platform are quite different before and after correction, the Shenzhen stock exchange requires the company to explain the reasons and whether it has used “the sales proportion of the kit in Amazon America is very small” to induce investors to infer the overall sales situation.
It is noteworthy that Andon Health Co.Ltd(002432) continues to “release good” on the interactive easy platform while receiving the attention letter. That morning, the company said on the interactive easy platform that its export products enjoyed the export tax rebate policy.
Andon Health Co.Ltd(002432) the share price went straight to the limit again. So far, the company’s share price has recorded 8 limits in 10 trading days, with a cumulative increase of 104.03%.
If you stretch it a little longer, the rise of Andon Health Co.Ltd(002432) share price has been even more amazing since early November, from more than 6 yuan to the latest 38.52 yuan, an increase of more than 5 times.
The reason why the stock price can get out of such a strong market began on November 8. On the same day, the company issued a notice of authorization from the U.S. Food and Drug Administration (FDA) EUA. Subsequently, the company said on the investor relations interactive platform that the production capacity of its covid-19 antigen home self-test OTC kit would be expanded to 200 million people per month.
The last time the company went out of such a strong market was in the first half of 2020, Andon Health Co.Ltd(002432) doubled the market with the anti epidemic plate due to the shortage of forehead temperature guns and other products.
Although the U.S. Food and Drug Administration’s EUA authorization is scarce, some people in the industry reminded reporters in an interview that EUA certification is not once and for all. Because the filtration rate did not meet the standard, on May 7, 2021, FDA revoked the EUA authorization of more than 60 mask manufacturers. Andon Health Co.Ltd(002432) the ability to continuously monitor the mutant virus is the best help to ensure its future sales.
Compared with peer companies, although the Omicron mutant strain came suddenly, different from the “waiting for the arrival of the strain” described in Andon Health Co.Ltd(002432) , many detection reagent companies have confirmed the effectiveness of their kits.
On November 27, Jiangsu Bioperfectus Technologies Co.Ltd(688399) said that the company’s covid-19 test kit could effectively detect Omicron virus; The official account of Shanghai Zj Bio-Tech Co.Ltd(688317) WeChat said in November 28th that the company could detect and identify viruses including Omicron and other variants, and there would be no miss and missed detection. Zhejiang Orient Gene Biotech Co.Ltd(688298) also said that the company’s covid-19 detection kit can effectively detect Omicron virus.
In addition, it is noteworthy that Andon Health Co.Ltd(002432) once said in the interactive Q & A that the production capacity is the production capacity, which can not be inferred as the actual output, let alone the actual sales volume.
A brokerage research report pointed out that from the perspective of the whole medical device industry, the performance volume of anti epidemic products has begun to shrink significantly in the third quarter of 2021, and the impact of the epidemic on performance tends to weaken.
Looking back on the financial report data of Andon Health Co.Ltd(002432) recent five years, non recurring profit and loss is the main factor for the company’s performance to turn around.
Before the outbreak, the company’s operating income was flat. From 2016 to 2019, the company’s operating revenue was 420 million yuan, 598 million yuan, 564 million yuan and 706 million yuan respectively, but it increased by leaps and bounds to 2.008 billion yuan in 2020. The net profit attributable to the parent company also shows the same trend.
On October 29, 2021, Andon Health Co.Ltd(002432) released the third quarter report. As of September 30, 2021, the company had achieved an operating revenue of 790 million yuan and a net profit attributable to the parent company of 50.128 million yuan, a decrease of 86.19% over the same period of the previous year. Previously, the deduction of non net profit of the company was negative for many years.
(Shanghai Securities News)
